McKesson Corp (McKesson) is a healthcare services and information technology company that provides pharmaceuticals, medical supplies, and healthcare management tools. It serves various sectors, including retail pharmacies, hospitals, health systems, and biopharma companies, primarily in North America. McKesson operates a network of 27 distribution centers in the US, including two strategic redistribution centers, and a national network of distribution centers in Canada. The company serves approximately 336,000 customers, including physician offices, surgery centers, and home health agencies. McKesson's Canadian retail business operates around 2,600 independent pharmacies under five nationally recognized banners. The company partners with manufacturers and channel partners to support key markets, including ambulatory care and extended care. The company markets its products under the brand names of McKesson ConnectSM, Central FillSM, and McKesson SynerGx.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

McKesson's R&D combined with Sarah Cannon Research Institute and its technology business, Ontada, provides research, insights, technologies, and services that address and improve cancer and specialty care. This segment was previously part of the former U.S. Pharmaceutical reportable segment. The company's clinical research offerings compete with contract research organizations, site management organizations, academic medical centers, and health systems that support clinical trials. The R&D units of McKesson are the Sarah Cannon Research Institute and Ontada. These units are responsible for providing research, insights, technologies, and services to improve cancer and specialty care. In FY2026, the company spent US$103 million on its R&D activities, which grew 13.2% YoY.